跳至主要内容
临床试验/NCT02000466
NCT02000466撤回不适用

FluLaval® Quadrivalent Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Any Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With FluLaval® Quadrivalent During Pregnancy or Within 28 Days Preceding Conception

GlaxoSmithKline0 个研究点开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
主要终点
Occurrence of any abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with FluLaval Quadrivalent during pregnancy or within 28 days preceding conception

研究概览

简要总结

The purpose of this pregnancy registry study is to detect and describe any abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with FluLaval Quadrivalent. The Registry requires voluntary, prospective reporting of eligible pregnancies by patients and health care providers (HCPs). Data such as vaccination with FluLaval Quadrivalent during pregnancy or within 28 days preceding conception, potential confounding factors (such as exposure to other medications) and information related to the outcome of the pregnancy will be collected prospectively.

详细描述

Some pregnancy exposures may be reported after pregnancy outcome has been identified (retrospective reports). The Registry will capture retrospective reports, but these reports will not be included in the analyses of prospective reports.

Pregnancy outcome data will be collected using questionnaires within 3 months of the estimated date of delivery (EDD) and approximately 6 months and 12 months after the EDD from 30 November 2013 to 31 May 2018.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
12 Years 至 64 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • A subject will be included in the Registry if all of the following criteria are met:
  • Exposure to vaccine occurs during pregnancy or within 28 days preceding conception.
  • Subject is a US resident.
  • A HCP is identified (name, address and phone number).
  • Subject can be identified (by GSK or HCP).
  • Data from registered subjects will be included in the analyses if the following criterion is met:
  • Pregnancy is ongoing and the outcome is unknown.

排除标准

  • Data from registered subjects will not be included in the analyses if the following criterion is met:
  • Outcome of pregnancy is known at the time of initial report. Types of known outcomes include prenatal testing reports in which the results are abnormal or outside the reference range, indicating possible abnormality in the fetus. Pregnancies in which prenatal testing indicates a normal pregnancy would also be excluded because inclusion of such pregnancies could potentially bias results toward a lower overall estimate of risk for defects. Typically pregnancies > 16 weeks gestation will have undergone prenatal testing that can identify whether a child has congenital abnormalities.

结局指标

主要结局

Occurrence of any abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with FluLaval Quadrivalent during pregnancy or within 28 days preceding conception

时间窗: Up to 12 months after EDD

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

FluLaval® Quadrivalent Pregnancy Registry | 临床试验